72nd Parliamentary Standing Committee Report On Alleged Irregularities in the Conduct Of Studies Using Human Papilloma Virus (Hpv) Vaccine By Path In India .
During March, 2010 the entire world was shocked by the media reports about the deaths of some female children and adolescents in Khammam district of Andhra Pradesh after being administered Human Papilloma Virus (HPV) vaccines. The vaccination trials were carried out by an American agency viz. Programme for Appropriate Technology in Health (PATH). The project was reportedly funded by Bill and Melinda Gates Foundation, an American charity.
“Alleged Irregularities in the Conduct of Studies Using Human Papilloma Virus (HPV) Vaccine” by Programme for Appropriate Technology in Health(PATH) in India.
“It is established that PATH by carrying out the clinical trials for HPV vaccines in Andhra Pradesh and Gujarat under the pretext of observation/demonstration project has violated laws and regulations laid down for clinical trials by the Government.
While doing so, its sole aim has been to promote the commercial interests of HPV vaccine manufacturers who would have reaped windfall profits PATH been successful in getting the HPV vaccine included in the UIP the Country. This is a serious breach of trust by any entity as the project involved life and safety of girl children and adolescents who were mostly unaware of the implications of vaccination.
The violation is also a serious breach of medical ethics. This act of PATH is a clear cut violation of human rights of these girl children and adolescents. It also deems it established case of child abuse. The Committee, therefore, recommends action by the Government against PATH. The Committee also desires that the National Human Rights Commission and National Commission Protection of Children Rights may take up this matter from the point view of the violation of human rights and child abuse. The National Commission for Women should also suo motu take cognizance of this case as all the poor and hapless subjects are females.
Be the first to comment